Keywords
Pulmonary Medicine ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

- 2/15/21 - 1 form, 21 itemgroups, 47 items, 1 language
Itemgroups: Administrative, Pharmacokinetics - Blood Sample (Odd Numbered Subjects) (Day 7), Pharmacokinetics - Blood Sample (Even Numbered Subjects) (Day 7) , Pharmacodynamics - Blood Sample (Day 7), Pharmacodynamics Urine Cortisol (Day 7 - Post-Dose), Local Laboratory - Clinical Chemistry (Day 7 - Pre-Dose), Local Laboratory - Clinical Chemistry (Day 7 - Pre-Dose) , Local Laboratory - Haematology (Day 7 - Pre-Dose), Local Laboratory - Haematology (Day 7 - Pre-Dose) , Urinalysis - Local (Day 7 - Pre-Dose), Urinalysis - Local (Day 7 - Pre-Dose) , Urinalysis - Microscopy (Day 7 - Pre-Dose) , Urinalysis - Microscopy (Day 7 - Pre-Dose) , Clinical Chemistry (Day 7 - Post-Dose) , Local Laboratory - Clinical Chemistry (Day 7 - Post-Dose) , Local Laboratory - Haematology (Day 7 - Post-Dose) , Local Laboratory - Haematology (Day 7 - Post-Dose), Urinalysis - Local (Day 7 - Post-Dose) , Urinalysis - Local (Day 7 - Post-Dose), Urinalysis - Microscopy (Day 7 - Post-Dose), Urinalysis - Microscopy (Day 7 - Post-Dose)
- 1/19/21 - 1 form, 18 itemgroups, 59 items, 1 language
Itemgroups: Administrative, Non-Serious Adverse Events, Non-Serious Adverse Events , Serious Adverse Event, Serious Adverse Event - Section 1, Serious Adverse Event - Section 1 , Serious Adverse Event - Section 2 (Seriousness), Serious Adverse Event - Section 3 (Demography Data), Serious Adverse Event - Section 4, Serious Adverse Event - Section 5, Serious Adverse Event - Section 6 (Relevant Medical Conditions), Serious Adverse Event - Section 7, Serious Adverse Event - Section 8 (Concomitant Medication), Serious Adverse Event - Section 9 (Details of Investigational Product(s)), Serious Adverse Event - Section 9 (Details of Investigational Product(s)) , Serious Adverse Event - Section 10, Serious Adverse Event - Section 11, Investigator's signature